Literature DB >> 24573377

Anti-Müllerian hormone (AMH): a reliable biomarker of oocyte quality in IVF.

Pierre Lehmann1, Maria P Vélez, Julio Saumet, Louise Lapensée, Wael Jamal, François Bissonnette, Simon Phillips, Isaac-Jacques Kadoch.   

Abstract

PURPOSE: To evaluate the impact of serum AMH levels on stimulated IVF implantation and clinical pregnancy rates.
METHODS:
DESIGN: Retrospective study with multivariate analysis. •
SETTING: Clinique ovo (Montreal University affiliated Center). • PATIENT(S): Six hundred and thirty seven patients undergoing a stimulated IVF protocol were included. Only non-polycystic ovary patients at their first IVF attempt were considered for the analysis. • INTERVENTION(S): None. • MAIN OUTCOME MEASURES(S): Implantation and ongoing pregnancy rates. RESULT(S): Cycle outcomes were analysed according to AMH percentiles based on the AMH normogram per patient's age of our infertile population. Multivariate analyses were done to adjust for potential confounding factors such as age, total exogenous FSH dosage and number of eggs retrieved. Compared to the reference population, a significant lower mean implantation rate (0.26 vs 0.45) was observed in patients under 35 years of age with AMH < 1 ng/ml. Women with AMH < 25th percentile had less chances of having an embryo transferred, lower chances of having an ongoing pregnancy per started IVF cycle and a lower embryo freezing rate compared to the reference population. CONCLUSION(S): Patients with AMH < 0.47 ng/ml should be advised before starting a stimulated IVF cycle of the poorer prognosis compared to our reference population independently of their age, total exogenous FSH dosage and number of eggs retrieved. Therefore, AMH could enable a more individualized number of embryo transfer policy based on oocyte quality.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24573377      PMCID: PMC3969465          DOI: 10.1007/s10815-014-0193-4

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  34 in total

1.  Prevention of age-related aneuploidies by polar body testing of oocytes.

Authors:  Y Verlinsky; J Cieslak; V Ivakhnenko; S Evsikov; G Wolf; M White; A Lifchez; B Kaplan; J Moise; J Valle; N Ginsberg; C Strom; A Kuliev
Journal:  J Assist Reprod Genet       Date:  1999-04       Impact factor: 3.412

2.  The cumulative embryo score: a predictive embryo scoring technique to select the optimal number of embryos to transfer in an in-vitro fertilization and embryo transfer programme.

Authors:  C V Steer; C L Mills; S L Tan; S Campbell; R G Edwards
Journal:  Hum Reprod       Date:  1992-01       Impact factor: 6.918

3.  Anti-Mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause.

Authors:  Antonio La Marca; Vincenzo De Leo; Simone Giulini; Raoul Orvieto; Stefania Malmusi; Luca Giannella; Annibale Volpe
Journal:  J Soc Gynecol Investig       Date:  2005-07-19

4.  Age-specific FSH levels as a tool for appropriate patient counselling in assisted reproduction.

Authors:  Andrea Weghofer; Markus Margreiter; Yvonne Fauster; Theresa Schaetz; Agnes Brandstetter; Doris Boehm; Wilfried Feichtinger
Journal:  Hum Reprod       Date:  2005-05-19       Impact factor: 6.918

5.  Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells.

Authors:  E Rajpert-De Meyts; N Jørgensen; N Graem; J Müller; R L Cate; N E Skakkebaek
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

6.  Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.

Authors:  André Hazout; Philippe Bouchard; David B Seifer; P Aussage; Anne Marie Junca; Paul Cohen-Bacrie
Journal:  Fertil Steril       Date:  2004-11       Impact factor: 7.329

7.  Anti-Mullerian hormone as a predictor of follicular reserve in ovarian insufficiency: special emphasis on FSH-resistant ovaries.

Authors:  S Kallio; K Aittomäki; T Piltonen; R Veijola; A Liakka; T E Vaskivuo; L Dunkel; J S Tapanainen
Journal:  Hum Reprod       Date:  2012-01-17       Impact factor: 6.918

8.  Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening.

Authors:  Tarun Jain; Michael R Soules; John A Collins
Journal:  Fertil Steril       Date:  2004-07       Impact factor: 7.329

9.  Mullerian inhibiting substance in humans: normal levels from infancy to adulthood.

Authors:  M M Lee; P K Donahoe; T Hasegawa; B Silverman; G B Crist; S Best; Y Hasegawa; R A Noto; D Schoenfeld; D T MacLaughlin
Journal:  J Clin Endocrinol Metab       Date:  1996-02       Impact factor: 5.958

10.  Anti-müllerian hormone is a promising predictor for the occurrence of the menopausal transition.

Authors:  Ilse A J van Rooij; Isolde den Tonkelaar; Frank J M Broekmans; Caspar W N Looman; Gabrielle J Scheffer; Frank H de Jong; Axel P N Themmen; Egbert R te Velde
Journal:  Menopause       Date:  2004 Nov-Dec       Impact factor: 2.953

View more
  16 in total

1.  Evaluation of serum anti-Mullerian hormone as a biomarker of early ovarian aging in young women undergoing IVF/ICSI cycle.

Authors:  Pin-Yao Lin; Fu-Jen Huang; Fu-Tsai Kung; Hsin-Ju Chiang; Yu-Ju Lin; Yi-Chi Lin; Kuo-Chung Lan
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 2.  Anti-müllerian hormone as a predictor for live birth among women undergoing IVF/ICSI in different age groups: an update of systematic review and meta-analysis.

Authors:  Ni-Jie Li; Qing-Yun Yao; Xiao-Qiong Yuan; Yong Huang; Yu-Feng Li
Journal:  Arch Gynecol Obstet       Date:  2022-07-30       Impact factor: 2.493

3.  The Effects of Follicular Fluid 25(OH)D Concentration on Intrafollicular Estradiol Level, Oocyte Quality, and Fertilization Rate in Women Who Underwent IVF Program.

Authors:  Christofani Ekapatria; Bayuaji Hartanto; Permadi Wiryawan; Djuwantono Tono; Tobing Maringan Diapari Lumban; Dhamayanti Meita; Boediono Arief; Mose Johanes Cornelius
Journal:  J Obstet Gynaecol India       Date:  2022-02-11

4.  Ovarian reserve and IVF outcomes in patients with inflammatory bowel disease: A systematic review and meta-analysis.

Authors:  Honghao Sun; Jiao Jiao; Feng Tian; Qing Liu; Jiansu Bian; Rongmin Xu; Da Li; Xiuxia Wang; Hong Shu
Journal:  EClinicalMedicine       Date:  2022-07-01

5.  Is Anti-Müllerian Hormone Associated With Fecundability? Findings From the EAGeR Trial.

Authors:  Shvetha M Zarek; Emily M Mitchell; Lindsey A Sjaarda; Sunni L Mumford; Robert M Silver; Joseph B Stanford; Noya Galai; Mark V White; Karen C Schliep; Alan H DeCherney; Enrique F Schisterman
Journal:  J Clin Endocrinol Metab       Date:  2015-09-25       Impact factor: 5.958

6.  Basal Serum Anti-Müllerian Hormone Level as a Predictor of Clinical Outcomes in Freezing-all Embryo Transfer Program.

Authors:  Xiao-Lan Li; Rui Huang; Cong Fang; Xiao-Yan Liang
Journal:  Curr Med Sci       Date:  2018-10-20

7.  Antimüllerian hormone and pregnancy loss from the Effects of Aspirin in Gestation and Reproduction trial.

Authors:  Shvetha M Zarek; Emily M Mitchell; Lindsey A Sjaarda; Sunni L Mumford; Robert M Silver; Joseph B Stanford; Noya Galai; Karen C Schliep; Rose G Radin; Torie C Plowden; Alan H DeCherney; Enrique F Schisterman
Journal:  Fertil Steril       Date:  2015-12-17       Impact factor: 7.329

8.  Female aging alters expression of human cumulus cells genes that are essential for oocyte quality.

Authors:  Tamadir Al-Edani; Said Assou; Alice Ferrières; Sophie Bringer Deutsch; Anna Gala; Charles-Henri Lecellier; Ounissa Aït-Ahmed; Samir Hamamah
Journal:  Biomed Res Int       Date:  2014-09-03       Impact factor: 3.411

Review 9.  Maximizing the clinical utility of antimüllerian hormone testing in women's health.

Authors:  Benjamin Leader; Valerie L Baker
Journal:  Curr Opin Obstet Gynecol       Date:  2014-08       Impact factor: 1.927

10.  Ovarian stimulation with human and recombinant gonadotropin - comparison of in vitro fertilization efficiency with use of time-lapse monitoring.

Authors:  Artur Wdowiak; Iwona Bojar
Journal:  Reprod Health       Date:  2015-12-15       Impact factor: 3.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.